BSV portfolio can touch ₹5,000 cr in 3-4 yrs'
Business Standard|July 29, 2024
In one of the biggest pharmaceutical (pharma) deals in recent years, Delhi-based Mankind Pharma acquired Mumbai-headquartered specialty pharma company Bharat Serums and Vaccines (BSV) for ₹13,630 crore on Friday. RAJEEV JUNEJA, managing director (MD) and vice-chairman of Mankind Pharma, spoke to Sohini Das over the phone about the potential of the BSV portfolio to reach a ₹5,000 crore turnover in three to four years with Mankind's marketing prowess. Edited excerpts:
Sohini Das

Will this deal lead to Mankind Pharma focusing on exports too?

We have been very clear from the beginning that we don't want to get into exports with generic or me-too products. We always wanted products with a high level of entry barriers and complexity.

With the BSV deal, we now have branded products in some cases, there is no competition, and in others, there is limited competition (one or two players). For example, consider the AntiD product that BSV hasnearly 5-7 per cent of Indian mothers are Rh negative (blood group), which amounts to 8-10 million mothers.

Lack of preventive measures can cause brain damage or jaundice in & newborns. The mother needs to take a dose in the third trimester and within 72 hours after delivery with an Rh-positive child. Only 3040 per cent of expecting mothers adhere to this due to lack of awareness. BSV has the world's first and only recombinant for AntiRhoD, which has a valid patent until 2028. It also has vertically integrated in-house cell lines. If anyone tries to make any product of BSV, it would take five to 10 years at least. But we also feel there is huge potential for these products in the Indian market itself. Even after acquiring BSV, 87 per cent of the revenues of the entity will come from India. Wherever we have strong opportunities in the rest of the world, we will pursue them. Our ambition is to become a great company in India.

How do you wish to grow the synergies between BSV and Mankind?

Probably the fastest-growing therapy segment is infertility treatment. People are marrying late, then deciding to have a baby later on in their lives, focusing on careers, stress-myriad factors are affecting fertility.

Diese Geschichte stammt aus der July 29, 2024-Ausgabe von Business Standard.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

Diese Geschichte stammt aus der July 29, 2024-Ausgabe von Business Standard.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

WEITERE ARTIKEL AUS BUSINESS STANDARDAlle anzeigen
Supreme Industries stock slips on weak Q2 showing
Business Standard

Supreme Industries stock slips on weak Q2 showing

Brokerages cut earnings estimates after firm disappointed the Street

time-read
2 Minuten  |
November 05, 2024
Business Standard

Dabur stock fall may provide entry to long-term investors

Dabur's performance in the July-September quarter of the current financial year (Q2FY25) was weak but in line with consensus. Consolidated revenue declined 5 per cent year-on-year (Y-o-Y) due to a temporary adjustment in General Trade (GT) inventory.

time-read
2 Minuten  |
November 05, 2024
Business Standard

Capital markets' boom drives NSE Q2 PAT up 57% at ₹3.14K crore

The National Stock Exchange (NSE) reported a 57 per cent year-on-year (Y-o-Y) jump in consolidated net profit to ₹3,137 crore during the quarter ended September 2024 (Q2 FY25) amid a boom in the capital markets.

time-read
1 min  |
November 05, 2024
Business Standard

Sebi directs Embassy Reit to suspend CEO Aravind Maiya

The Securities and Exchange Board of India (Sebi) on Monday directed Embassy Office Parks Management Services, manager to the Embassy Real Estate Investment Trust (Reit), to suspend its chief executive officer Aravind Maiya for lapses in the \"fit and proper\" criteria.

time-read
1 min  |
November 05, 2024
Business Standard

Quant MF expects market correction to pave the way for risk-on phase

The recent downturn in the equity market may see a reversal once the US elections are over, according to Quant Mutual Fund, which emphasizes that the last month's correction should be seen as an opportunity to build more resilient and rewarding portfolios.

time-read
1 min  |
November 05, 2024
Mid, smallcap bounceback may be a distant dream
Business Standard

Mid, smallcap bounceback may be a distant dream

Analysts believe markets lack positive triggers for an immediate turnaround amid looming US polls

time-read
2 Minuten  |
November 05, 2024
Business Standard

Sebi allows MFs to invest in overseas schemes with India exposure

The Securities and Exchange Board of India (Sebi) has allowed mutual funds (MFs) to invest in overseas funds and unit trusts (UTs) that have up to 25 per cent exposure to Indian equities.

time-read
1 min  |
November 05, 2024
Business Standard

Worst not over yet? Mkt selloff may continue amid headwinds

Technical charts suggest Sensex can slide to 72,000 levels in the worst-case scenario

time-read
3 Minuten  |
November 05, 2024
Business Standard

New York Times beats estimates as digital subscriber count grows

New York Times Co reported third-quarter earnings that beat analysts' expectations, as the company saw an increase in its subscriber count in the months leading up to the 2024 Presidential Election.

time-read
1 min  |
November 05, 2024
Business Standard

Pak blames 'winds from India' as Lahore AQI hits record high

Ministers in Pakistan's Punjab province on Monday blamed winds from India for worsening the smog, urging the Indian authorities to take the matter seriously, after the air quality index (AQI) in Lahore hit a record high over the weekend.

time-read
1 min  |
November 05, 2024